APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neurofibromatoses Type II Therapecutics

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Neurofibromatoses Type II Therapecutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025182 pages

Choose your research edition.

Industry ResearchNeurofibromatoses Type II Therapecutics Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Neurofibromatoses Type II Therapecutics Industry Growth and Trends Forecast to 203294 pages · $3,450 USDMarket StructureGlobal Neurofibromatoses Type II Therapecutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neurofibromatoses Type II Therapecutics Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Neurofibromatoses Type II Therapecutics Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Neurofibromatoses Type II Therapecutics market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Neurofibromatoses Type II Therapecutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Neurofibromatoses Type II Therapecutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Neurofibromatoses Type II Therapecutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Neurofibromatoses Type II Therapecutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Neurofibromatoses Type II Therapecutics include AstraZeneca Plc, Recursion Pharmaceuticals Inc, Plex Pharmaceuticals Inc, Lixte Biotechnology Holdings Inc, Beta Pharma Inc and Arno Therapeutics Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Neurofibromatoses Type II Therapecutics market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Neurofibromatoses Type II Therapecutics and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Neurofibromatoses Type II Therapecutics sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Neurofibromatoses Type II Therapecutics market size, projected growth trends, production technologies, key applications, and end-use industries.

Neurofibromatoses Type II Therapecutics Segment by Company

AstraZeneca Plc

Recursion Pharmaceuticals Inc

Plex Pharmaceuticals Inc

Lixte Biotechnology Holdings Inc

Beta Pharma Inc

Arno Therapeutics Inc

Neurofibromatoses Type II Therapecutics Segment by Type

LB-205

LB-201

Icotinib Hydrochloride

FRAX-597

AR-42

Others

Neurofibromatoses Type II Therapecutics Segment by Application

Clinic

Hospital

Home Care

Neurofibromatoses Type II Therapecutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neurofibromatoses Type II Therapecutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neurofibromatoses Type II Therapecutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neurofibromatoses Type II Therapecutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Neurofibromatoses Type II Therapecutics market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Neurofibromatoses Type II Therapecutics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Neurofibromatoses Type II Therapecutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Neurofibromatoses Type II Therapecutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Neurofibromatoses Type II Therapecutics Industry Trends Table 2. Neurofibromatoses Type II Therapecutics Industry Drivers Table 3. Neurofibromatoses Type II Therapecutics Industry Opportunities and Challenges Table 4. Neurofibromatoses Type II Therapecutics Industry Restraints Table 5. Global Neurofibromatoses Type II Therapecutics Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Neurofibromatoses Type II Therapecutics Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Neurofibromatoses Type II Therapecutics Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Neurofibromatoses Type II Therapecutics Sales Market Share by Manufacturers Table 9. Global Neurofibromatoses Type II Therapecutics Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Neurofibromatoses Type II Therapecutics Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Neurofibromatoses Type II Therapecutics Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Neurofibromatoses Type II Therapecutics Manufacturers, Product Type & Application Table 13. Global Neurofibromatoses Type II Therapecutics Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Neurofibromatoses Type II Therapecutics by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of LB-205 Table 17. Major Manufacturers of LB-201 Table 18. Major Manufacturers of Icotinib Hydrochloride Table 19. Major Manufacturers of FRAX-597 Table 20. Major Manufacturers of AR-42 Table 21. Major Manufacturers of Others Table 22. Global Neurofibromatoses Type II Therapecutics Sales by Type 2021 VS 2025 VS 2032 (k units) Table 23. Global Neurofibromatoses Type II Therapecutics Sales by Type (2021-2026) & (k units) Table 24. Global Neurofibromatoses Type II Therapecutics Sales by Type (2027-2032) & (k units) Table 25. Global Neurofibromatoses Type II Therapecutics Sales Market Share by Type (2021-2026) Table 26. Global Neurofibromatoses Type II Therapecutics Sales Market Share by Type (2027-2032) Table 27. Global Neurofibromatoses Type II Therapecutics Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 28. Global Neurofibromatoses Type II Therapecutics Revenue by Type (2021-2026) & (k units) Table 29. Global Neurofibromatoses Type II Therapecutics Revenue by Type (2027-2032) & (k units) Table 30. Global Neurofibromatoses Type II Therapecutics Revenue Market Share by Type (2021-2026) Table 31. Global Neurofibromatoses Type II Therapecutics Revenue Market Share by Type (2027-2032) Table 32. Major Manufacturers of Clinic Table 33. Major Manufacturers of Hospital Table 34. Major Manufacturers of Home Care Table 35. Global Neurofibromatoses Type II Therapecutics Sales by Application 2021 VS 2025 VS 2032 (k units) Table 36. Global Neurofibromatoses Type II Therapecutics Sales by Application (2021-2026) & (k units) Table 37. Global Neurofibromatoses Type II Therapecutics Sales by Application (2027-2032) & (k units) Table 38. Global Neurofibromatoses Type II Therapecutics Sales Market Share by Application (2021-2026) Table 39. Global Neurofibromatoses Type II Therapecutics Sales Market Share by Application (2027-2032) Table 40. Global Neurofibromatoses Type II Therapecutics Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 41. Global Neurofibromatoses Type II Therapecutics Revenue by Application (2021-2026) & (k units) Table 42. Global Neurofibromatoses Type II Therapecutics Revenue by Application (2027-2032) & (k units) Table 43. Global Neurofibromatoses Type II Therapecutics Revenue Market Share by Application (2021-2026) Table 44. Global Neurofibromatoses Type II Therapecutics Revenue Market Share by Application (2027-2032) Table 45. Global Neurofibromatoses Type II Therapecutics Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 46. Global Neurofibromatoses Type II Therapecutics Sales by Region (2021-2026) & (k units) Table 47. Global Neurofibromatoses Type II Therapecutics Sales Market Share by Region (2021-2026) Table 48. Global Neurofibromatoses Type II Therapecutics Sales Forecasted by Region (2027-2032) & (k units) Table 49. Global Neurofibromatoses Type II Therapecutics Sales Forecasted Market Share by Region (2027-2032) Table 50. North America Neurofibromatoses Type II Therapecutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 51. North America Neurofibromatoses Type II Therapecutics Sales by Country (2021-2026) & (k units) Table 52. North America Neurofibromatoses Type II Therapecutics Sales by Country (2027-2032) & (k units) Table 53. Europe Neurofibromatoses Type II Therapecutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 54. Europe Neurofibromatoses Type II Therapecutics Sales by Country (2021-2026) & (k units) Table 55. Europe Neurofibromatoses Type II Therapecutics Sales by Country (2027-2032) & (k units) Table 56. Asia Pacific Neurofibromatoses Type II Therapecutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 57. Asia Pacific Neurofibromatoses Type II Therapecutics Sales by Country (2021-2026) & (k units) Table 58. Asia Pacific Neurofibromatoses Type II Therapecutics Sales by Country (2027-2032) & (k units) Table 59. South America, Middle East and Africa Neurofibromatoses Type II Therapecutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 60. South America, Middle East and Africa Neurofibromatoses Type II Therapecutics Sales by Country (2021-2026) & (k units) Table 61. South America, Middle East and Africa Neurofibromatoses Type II Therapecutics Sales by Country (2027-2032) & (k units) Table 62. Global Neurofibromatoses Type II Therapecutics Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Global Neurofibromatoses Type II Therapecutics Revenue by Region (2021-2026) & (US$ Million) Table 64. Global Neurofibromatoses Type II Therapecutics Revenue by Region (2027-2032) & (US$ Million) Table 65. Global Neurofibromatoses Type II Therapecutics Revenue Market Share by Region (2021-2026) Table 66. Global Neurofibromatoses Type II Therapecutics Revenue Market Share by Region (2027-2032) Table 67. AstraZeneca Plc Company Information Table 68. AstraZeneca Plc Business Overview Table 69. AstraZeneca Plc Neurofibromatoses Type II Therapecutics Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. AstraZeneca Plc Neurofibromatoses Type II Therapecutics Product Portfolio Table 71. AstraZeneca Plc Recent Development Table 72. Recursion Pharmaceuticals Inc Company Information Table 73. Recursion Pharmaceuticals Inc Business Overview Table 74. Recursion Pharmaceuticals Inc Neurofibromatoses Type II Therapecutics Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Recursion Pharmaceuticals Inc Neurofibromatoses Type II Therapecutics Product Portfolio Table 76. Recursion Pharmaceuticals Inc Recent Development Table 77. Plex Pharmaceuticals Inc Company Information Table 78. Plex Pharmaceuticals Inc Business Overview Table 79. Plex Pharmaceuticals Inc Neurofibromatoses Type II Therapecutics Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Plex Pharmaceuticals Inc Neurofibromatoses Type II Therapecutics Product Portfolio Table 81. Plex Pharmaceuticals Inc Recent Development Table 82. Lixte Biotechnology Holdings Inc Company Information Table 83. Lixte Biotechnology Holdings Inc Business Overview Table 84. Lixte Biotechnology Holdings Inc Neurofibromatoses Type II Therapecutics Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Lixte Biotechnology Holdings Inc Neurofibromatoses Type II Therapecutics Product Portfolio Table 86. Lixte Biotechnology Holdings Inc Recent Development Table 87. Beta Pharma Inc Company Information Table 88. Beta Pharma Inc Business Overview Table 89. Beta Pharma Inc Neurofibromatoses Type II Therapecutics Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Beta Pharma Inc Neurofibromatoses Type II Therapecutics Product Portfolio Table 91. Beta Pharma Inc Recent Development Table 92. Arno Therapeutics Inc Company Information Table 93. Arno Therapeutics Inc Business Overview Table 94. Arno Therapeutics Inc Neurofibromatoses Type II Therapecutics Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Arno Therapeutics Inc Neurofibromatoses Type II Therapecutics Product Portfolio Table 96. Arno Therapeutics Inc Recent Development Table 97. Key Raw Materials Table 98. Raw Materials Key Suppliers Table 99. Neurofibromatoses Type II Therapecutics Distributors List Table 100. Neurofibromatoses Type II Therapecutics Customers List Table 101. Research Programs/Design for This Report Table 102. Authors List of This Report Table 103. Secondary Sources Table 104. Primary Sources List of Figures Figure 1. Neurofibromatoses Type II Therapecutics Product Image Figure 2. Global Neurofibromatoses Type II Therapecutics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neurofibromatoses Type II Therapecutics Market Size (2021-2032) & (US$ Million) Figure 4. Global Neurofibromatoses Type II Therapecutics Sales (2021-2032) & (k units) Figure 5. Global Neurofibromatoses Type II Therapecutics Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Neurofibromatoses Type II Therapecutics Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. LB-205 Image Figure 9. LB-201 Image Figure 10. Icotinib Hydrochloride Image Figure 11. FRAX-597 Image Figure 12. AR-42 Image Figure 13. Others Image Figure 14. Global Neurofibromatoses Type II Therapecutics Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 15. Global Neurofibromatoses Type II Therapecutics Sales Market Share 2021 VS 2025 VS 2032 Figure 16. Global Neurofibromatoses Type II Therapecutics Sales Market Share by Type (2021-2032) Figure 17. Global Neurofibromatoses Type II Therapecutics Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 18. Global Neurofibromatoses Type II Therapecutics Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Neurofibromatoses Type II Therapecutics Revenue Market Share by Type (2021-2032) Figure 20. Clinic Image Figure 21. Hospital Image Figure 22. Home Care Image Figure 23. Global Neurofibromatoses Type II Therapecutics Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 24. Global Neurofibromatoses Type II Therapecutics Sales Market Share 2021 VS 2025 VS 2032 Figure 25. Global Neurofibromatoses Type II Therapecutics Sales Market Share by Application (2021-2032) Figure 26. Global Neurofibromatoses Type II Therapecutics Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 27. Global Neurofibromatoses Type II Therapecutics Revenue Market Share 2021 VS 2025 VS 2032 Figure 28. Global Neurofibromatoses Type II Therapecutics Revenue Market Share by Application (2021-2032) Figure 29. North America Neurofibromatoses Type II Therapecutics Sales and Growth Rate (2021-2032) & (k units) Figure 30. North America Neurofibromatoses Type II Therapecutics Sales Market Share by Country (2021-2032) Figure 31. U.S. Neurofibromatoses Type II Therapecutics Sales and Growth Rate (2021-2032) & (k units) Figure 32. Canada Neurofibromatoses Type II Therapecutics Sales and Growth Rate (2021-2032) & (k units) Figure 33. Mexico Neurofibromatoses Type II Therapecutics Sales and Growth Rate (2021-2032) & (k units) Figure 34. Europe Neurofibromatoses Type II Therapecutics Sales and Growth Rate (2021-2032) & (k units) Figure 35. Europe Neurofibromatoses Type II Therapecutics Sales Market Share by Country (2021-2032) Figure 36. Germany Neurofibromatoses Type II Therapecutics Sales and Growth Rate (2021-2032) & (k units) Figure 37. France Neurofibromatoses Type II Therapecutics Sales and Growth Rate (2021-2032) & (k units) Figure 38. U.K. Neurofibromatoses Type II Therapecutics Sales and Growth Rate (2021-2032) & (k units) Figure 39. Italy Neurofibromatoses Type II Therapecutics Sales and Growth Rate (2021-2032) & (k units) Figure 40. Netherlands Neurofibromatoses Type II Therapecutics Sales and Growth Rate (2021-2032) & (k units) Figure 41. Asia Pacific Neurofibromatoses Type II Therapecutics Sales and Growth Rate (2021-2032) & (k units) Figure 42. Asia Pacific Neurofibromatoses Type II Therapecutics Sales Market Share by Country (2021-2032) Figure 43. China Neurofibromatoses Type II Therapecutics Sales and Growth Rate (2021-2032) & (k units) Figure 44. Japan Neurofibromatoses Type II Therapecutics Sales and Growth Rate (2021-2032) & (k units) Figure 45. South Korea Neurofibromatoses Type II Therapecutics Sales and Growth Rate (2021-2032) & (k units) Figure 46. Southeast Asia Neurofibromatoses Type II Therapecutics Sales and Growth Rate (2021-2032) & (k units) Figure 47. India Neurofibromatoses Type II Therapecutics Sales and Growth Rate (2021-2032) & (k units) Figure 48. Australia Neurofibromatoses Type II Therapecutics Sales and Growth Rate (2021-2032) & (k units) Figure 49. South America, Middle East and Africa Neurofibromatoses Type II Therapecutics Sales and Growth Rate (2021-2032) & (k units) Figure 50. South America, Middle East and Africa Neurofibromatoses Type II Therapecutics Sales Market Share by Country (2021-2032) Figure 51. Brazil Neurofibromatoses Type II Therapecutics Sales and Growth Rate (2021-2032) & (k units) Figure 52. South Africa Neurofibromatoses Type II Therapecutics Sales and Growth Rate (2021-2032) & (k units) Figure 53. Saudi Arabia Neurofibromatoses Type II Therapecutics Sales and Growth Rate (2021-2032) & (k units) Figure 54. Turkey Neurofibromatoses Type II Therapecutics Sales and Growth Rate (2021-2032) & (k units) Figure 55. Argentina Neurofibromatoses Type II Therapecutics Sales and Growth Rate (2021-2032) & (k units) Figure 56. UAE Neurofibromatoses Type II Therapecutics Sales and Growth Rate (2021-2032) & (k units) Figure 57. Egypt Neurofibromatoses Type II Therapecutics Sales and Growth Rate (2021-2032) & (k units) Figure 58. Chile Neurofibromatoses Type II Therapecutics Sales and Growth Rate (2021-2032) & (k units) Figure 59. Global Neurofibromatoses Type II Therapecutics Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Global Neurofibromatoses Type II Therapecutics Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 61. North America Neurofibromatoses Type II Therapecutics Revenue (2021-2032) & (US$ Million) Figure 62. North America Neurofibromatoses Type II Therapecutics Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Europe Neurofibromatoses Type II Therapecutics Revenue (2021-2032) & (US$ Million) Figure 64. Europe Neurofibromatoses Type II Therapecutics Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Asia-Pacific Neurofibromatoses Type II Therapecutics Revenue (2021-2032) & (US$ Million) Figure 66. Asia-Pacific Neurofibromatoses Type II Therapecutics Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. South America, Middle East and Africa Neurofibromatoses Type II Therapecutics Revenue (2021-2032) & (US$ Million) Figure 68. South America, Middle East and Africa Neurofibromatoses Type II Therapecutics Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. Neurofibromatoses Type II Therapecutics Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Neurofibromatoses Type II Therapecutics Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • LB-205
  • LB-201
  • Icotinib Hydrochloride
  • FRAX-597
  • AR-42
  • Others
Applications
  • Clinic
  • Hospital
  • Home Care
Companies covered
  • AstraZeneca Plc
  • Recursion Pharmaceuticals Inc
  • Plex Pharmaceuticals Inc
  • Lixte Biotechnology Holdings Inc
  • Beta Pharma Inc
  • Arno Therapeutics Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Neurofibromatoses Type II Therapecutics Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Neurofibromatoses Type II Therapecutics Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Neurofibromatoses Type II Therapecutics Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Neurofibromatoses Type II Therapecutics Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Neurofibromatoses Type II Therapecutics Market Dynamics
  1. 2.1 Neurofibromatoses Type II Therapecutics Industry Trends
  2. 2.2 Neurofibromatoses Type II Therapecutics Industry Drivers
  3. 2.3 Neurofibromatoses Type II Therapecutics Industry Opportunities and Challenges
  4. 2.4 Neurofibromatoses Type II Therapecutics Industry Restraints
3 Neurofibromatoses Type II Therapecutics Market by Manufacturers
  1. 3.1 Global Neurofibromatoses Type II Therapecutics Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Neurofibromatoses Type II Therapecutics Sales by Manufacturers (2021-2026)
  3. 3.3 Global Neurofibromatoses Type II Therapecutics Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Neurofibromatoses Type II Therapecutics Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Neurofibromatoses Type II Therapecutics Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Neurofibromatoses Type II Therapecutics Manufacturers, Product Type & Application
  7. 3.7 Global Neurofibromatoses Type II Therapecutics Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Neurofibromatoses Type II Therapecutics Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Neurofibromatoses Type II Therapecutics Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Neurofibromatoses Type II Therapecutics Tier 1, Tier 2, and Tier 3
4 Neurofibromatoses Type II Therapecutics Market by Type
  1. 4.1 Neurofibromatoses Type II Therapecutics Type Introduction
  2. 4.1.1 LB-205
  3. 4.1.2 LB-201
  4. 4.1.3 Icotinib Hydrochloride
  5. 4.1.4 FRAX-597
  6. 4.1.5 AR-42
  7. 4.1.6 Others
  8. 4.2 Global Neurofibromatoses Type II Therapecutics Sales by Type
  9. 4.2.1 Global Neurofibromatoses Type II Therapecutics Sales by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Neurofibromatoses Type II Therapecutics Sales by Type (2021-2032)
  11. 4.2.3 Global Neurofibromatoses Type II Therapecutics Sales Market Share by Type (2021-2032)
  12. 4.3 Global Neurofibromatoses Type II Therapecutics Revenue by Type
  13. 4.3.1 Global Neurofibromatoses Type II Therapecutics Revenue by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Neurofibromatoses Type II Therapecutics Revenue by Type (2021-2032)
  15. 4.3.3 Global Neurofibromatoses Type II Therapecutics Revenue Market Share by Type (2021-2032)
5 Neurofibromatoses Type II Therapecutics Market by Application
  1. 5.1 Neurofibromatoses Type II Therapecutics Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Home Care
  5. 5.2 Global Neurofibromatoses Type II Therapecutics Sales by Application
  6. 5.2.1 Global Neurofibromatoses Type II Therapecutics Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Neurofibromatoses Type II Therapecutics Sales by Application (2021-2032)
  8. 5.2.3 Global Neurofibromatoses Type II Therapecutics Sales Market Share by Application (2021-2032)
  9. 5.3 Global Neurofibromatoses Type II Therapecutics Revenue by Application
  10. 5.3.1 Global Neurofibromatoses Type II Therapecutics Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Neurofibromatoses Type II Therapecutics Revenue by Application (2021-2032)
  12. 5.3.3 Global Neurofibromatoses Type II Therapecutics Revenue Market Share by Application (2021-2032)
6 Global Neurofibromatoses Type II Therapecutics Sales by Region
  1. 6.1 Global Neurofibromatoses Type II Therapecutics Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Neurofibromatoses Type II Therapecutics Sales by Region (2021-2032)
  3. 6.2.1 Global Neurofibromatoses Type II Therapecutics Sales by Region (2021-2026)
  4. 6.2.2 Global Neurofibromatoses Type II Therapecutics Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Neurofibromatoses Type II Therapecutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Neurofibromatoses Type II Therapecutics Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Neurofibromatoses Type II Therapecutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Neurofibromatoses Type II Therapecutics Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Neurofibromatoses Type II Therapecutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Neurofibromatoses Type II Therapecutics Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Neurofibromatoses Type II Therapecutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Neurofibromatoses Type II Therapecutics Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Neurofibromatoses Type II Therapecutics Revenue by Region
  1. 7.1 Global Neurofibromatoses Type II Therapecutics Revenue by Region
  2. 7.1.1 Global Neurofibromatoses Type II Therapecutics Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Neurofibromatoses Type II Therapecutics Revenue by Region (2021-2026)
  4. 7.1.3 Global Neurofibromatoses Type II Therapecutics Revenue by Region (2027-2032)
  5. 7.1.4 Global Neurofibromatoses Type II Therapecutics Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Neurofibromatoses Type II Therapecutics Revenue (2021-2032)
  8. 7.2.2 North America Neurofibromatoses Type II Therapecutics Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Neurofibromatoses Type II Therapecutics Revenue (2021-2032)
  11. 7.3.2 Europe Neurofibromatoses Type II Therapecutics Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Neurofibromatoses Type II Therapecutics Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Neurofibromatoses Type II Therapecutics Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Neurofibromatoses Type II Therapecutics Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Neurofibromatoses Type II Therapecutics Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 AstraZeneca Plc
  2. 8.1.1 AstraZeneca Plc Company Information
  3. 8.1.2 AstraZeneca Plc Business Overview
  4. 8.1.3 AstraZeneca Plc Neurofibromatoses Type II Therapecutics Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 AstraZeneca Plc Neurofibromatoses Type II Therapecutics Product Portfolio
  6. 8.1.5 AstraZeneca Plc Recent Developments
  7. 8.2 Recursion Pharmaceuticals Inc
  8. 8.2.1 Recursion Pharmaceuticals Inc Company Information
  9. 8.2.2 Recursion Pharmaceuticals Inc Business Overview
  10. 8.2.3 Recursion Pharmaceuticals Inc Neurofibromatoses Type II Therapecutics Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Recursion Pharmaceuticals Inc Neurofibromatoses Type II Therapecutics Product Portfolio
  12. 8.2.5 Recursion Pharmaceuticals Inc Recent Developments
  13. 8.3 Plex Pharmaceuticals Inc
  14. 8.3.1 Plex Pharmaceuticals Inc Company Information
  15. 8.3.2 Plex Pharmaceuticals Inc Business Overview
  16. 8.3.3 Plex Pharmaceuticals Inc Neurofibromatoses Type II Therapecutics Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Plex Pharmaceuticals Inc Neurofibromatoses Type II Therapecutics Product Portfolio
  18. 8.3.5 Plex Pharmaceuticals Inc Recent Developments
  19. 8.4 Lixte Biotechnology Holdings Inc
  20. 8.4.1 Lixte Biotechnology Holdings Inc Company Information
  21. 8.4.2 Lixte Biotechnology Holdings Inc Business Overview
  22. 8.4.3 Lixte Biotechnology Holdings Inc Neurofibromatoses Type II Therapecutics Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Lixte Biotechnology Holdings Inc Neurofibromatoses Type II Therapecutics Product Portfolio
  24. 8.4.5 Lixte Biotechnology Holdings Inc Recent Developments
  25. 8.5 Beta Pharma Inc
  26. 8.5.1 Beta Pharma Inc Company Information
  27. 8.5.2 Beta Pharma Inc Business Overview
  28. 8.5.3 Beta Pharma Inc Neurofibromatoses Type II Therapecutics Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Beta Pharma Inc Neurofibromatoses Type II Therapecutics Product Portfolio
  30. 8.5.5 Beta Pharma Inc Recent Developments
  31. 8.6 Arno Therapeutics Inc
  32. 8.6.1 Arno Therapeutics Inc Company Information
  33. 8.6.2 Arno Therapeutics Inc Business Overview
  34. 8.6.3 Arno Therapeutics Inc Neurofibromatoses Type II Therapecutics Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Arno Therapeutics Inc Neurofibromatoses Type II Therapecutics Product Portfolio
  36. 8.6.5 Arno Therapeutics Inc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Neurofibromatoses Type II Therapecutics Value Chain Analysis
  2. 9.1.1 Neurofibromatoses Type II Therapecutics Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Neurofibromatoses Type II Therapecutics Production Mode & Process
  6. 9.2 Neurofibromatoses Type II Therapecutics Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Neurofibromatoses Type II Therapecutics Distributors
  9. 9.2.3 Neurofibromatoses Type II Therapecutics Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst